Kinarus is a Basel-based clinical-stage company focused on developing KIN001, a patented therapeutic candidate with potential across viral, respiratory, and ophthalmic indications. The company enrolled and dosed the first patient in the Phase 2 KINETIC trial of KIN001 in hospitalized COVID-19 patients in April. Kinarus is advancing a broader Phase 2 clinical portfolio, including plans to initiate a Phase 2 trial in Age-Related wet Macular Degeneration. To support these programs it is pursuing financing: a Series B round is currently underway prior to a planned public listing. The company has executed a capital-commitment agreement intended to provide additional liquidity post-listing to progress its clinical development.

Total raised

$62M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2021